Allan JN et al. Primary analysis of the fixed-duration cohort from the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021;Abstract S147.
Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021;39(31):3441-52. Abstract
Davids MS, Letai A. ABT-199: Taking dead aim at BCL-2. Cancer Cell 2013;23(2):139-41. Abstract
Freeman CL, Sehn LH. A tale of two antibodies: Obinutuzumab versus rituximab. Br J Haematol 2018;182(1):29-45. Abstract
Hillmen P et al. Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Interim analysis of a randomized phase III trial. J Clin Oncol 2023;41(5):1035-45. Abstract
Kater AP, Eichhorst B. Inhibiting BTK in chronic lymphocytic leukemia. N Engl J Med 2023;389:83-6. Abstract
Mato AR et al. Pritobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 2023;389(1):33-44. Abstract
Mato AR et al. NX-2127-001, a first-in-human trial of NX-2127, a Bruton’s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies. ASH 2022;Abstract 961.
Niemann CU et al. Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (ibr+ven) versus chlorambucil plus obinutuzumab (clb+o): The Glow study. ASH 2022;Abstract 93.
Robak T et al. The role of Bruton’s kinase inhibitors in chronic lymphocytic leukemia: Current status and future directions. Cancers (Basel) 2022;14(3):771. Abstract
Ryan CE et al. MAJIC: A phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol 2022;18(33):3689-99. Abstract
Siddiqi T et al. Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004. ASCO 2023;Abstract 7501.
Tedeschi A et al. Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Early results from Arm D of the SEQUOIA (BGB-3111-304) trial. ASH 2021;Abstract 67.